Dr. Chi-Meng Tzeng is a professorate senior engineer in the School of Pharmaceutical Sciences (SPS) and Translational Medicine Research Center (TMRC) at Xiamen University. He received graduated training in Tsing-Hua University School of Nuclear Science (1989~1993) and in Stanford University School of Medicine (1995-2000). Military service as a MD Captain at Tri-Service General Hospital in Neurology and OB&GYN (1993-1995). He was appointed to a principal Investigator in Medical R&D and industrialization at Academic Sinica and National Taiwan University Hospital (2000-2005), conducting fingerprint profiling of adenocarcinoma and herbal medicine through HTS biochips platform technologies.

In the past two decades, Dr. Tzeng started up Infinigen, U-Vision, INNOVA CellTDx, SUAN Health and JYK Gene, and worked for ABI, Beckman, AmoyDx as executive position to bring in values of revenue and reputation among academics, industry and government. Nowadays, he is fully dedicating in translational medicine puzzling with liquid biopsy, microbiota, neoantigen, -OMICs, immune-cell therapy, functional-MSCs, AI big health data mining, herbal medicine and combination theranostics to contribute over 70 SCIs articles, 4 book chapters, 20 patents and 14 commercial products (IVDs, supplements and medication). Meanwhile, Dr. Tzeng is executive director in charge of Xiamen Key Laboratory in Cancer T-Cells Theranostics Clinical Translation (CTCTCT), of Translation Medicine Research Center (TMRC) in SPS Xiamen University, and of Medical Research Center (MRC) Chang-Gung Hospital in Xiamen.

SPS:TMRC had trained over 8 MD, 9Ph.D, and over two-digits graduate students. Through integrating the-state-of-art All-Omics platform technologies, TMRC is still working on 1) Bio-marker deciphering in drug target, TDx and illness indicators; 2) Cell Theranostics in regenerative and immune-modulating cells; 3) Microbiota in GI and reproductive tracks; and 4) Biologics and gene medication including Alloferon, Ad-TP53, mAB-VEGF, MSCs and immune-cells

Translated commercial products from TMRC lab comprising 1) IVDs for EGFR, Brca1/2, SMA, VitD3, HER2, HPV, siRNAs, SARS-CoV-2 detection; 2) MSCs for Psoriasis, Osteoporosis and Wound healing treatment; 3) Immune cells (T-NeoAg/sug-NK/CAR-T) for cancer prevention and therapy by neoantigen vaccination, anti-EGFR-CarT, anti-CDR3-CarT and allogenic polysaccharides-NK cells.

TMRC notedly has been invited by Xiamen supervision in 2023 to establish the SOPs of cells drug production (IIT/IND grades) and guidance of QC/QA of cells and its associated EVs from the human resources of ucWJ-MSC, adi-MSC, and NK, DC/CIK, T cells, plus gene-editing CAR-T cell cassette.

Selected Publications (last 5 years):

1.        Zhang X, Retyunskiy V, Qiao S, Zhao Y, Tzeng CM. Alloferon-1 ameliorates acute inflammatory responses in λ-carrageenan-induced paw edema in mice. Sci Rep. 2022 Oct 6;12(1):16689. doi: 10.1038/s41598-022-20648-z. PMID: 36202869; PMCID: PMC9537184.

2.        Zhao Y, Wang T, Chen Z, Ren H, Song P, Zhu Y, Liang S, Tzeng C. Development and Evaluation of a Thermosensitive In Situ Gel Formulation for Intravaginal Delivery of Lactobacillus gasseri. Pharmaceutics. 2022 Sep 13;14(9):1934. doi: 10.3390/pharmaceutics14091934. PMID: 36145685; PMCID: PMC9501376.

3.        Lin TL, Lu CC, Lai WF, Wu TS, Lu JJ, Chen YM, Tzeng CM, Liu HT, Wei H, Lai HC. Role of gut microbiota in identification of novel TCM-derived active metabolites. Protein Cell. 2021 May;12(5):394-410. doi: 10.1007/s13238-020-00784-w. Epub 2021 Sep 15. PMID: 32929698; PMCID: PMC8106560.

4.        Chen Lin, Xuzhu Liu, Bingyi Zheng, Rongqin Ke, and Chi-Meng Tzeng, Liquid Biopsy, ctDNA Diagnosis through NGS, Life 2021, 11(9), 890, MDPI. doi: https://doi.org/10.3390/life11090890

5.        Huang WQ, Lin Q, Chen S, Sun L, Chen Q, Yi K, Li Z, Ma Q, Tzeng CM. Integrated analysis of microRNA and mRNA expression profiling identifies BAIAP3 as a novel target of dysregulated hsa-miR-1972 in age-related white matter lesions. Aging (Albany NY). 2021 Jun 14;13(11):15688-15689. doi:10.18632/aging.203217. Epub 2021 Jun 14. Erratum for: Aging (Albany NY).13:4674. PMID: 34127571; PMCID: PMC8221320.

6.        Jianghong Cheng, Mingli Li , Chi-Meng Tzeng , Xingchun Gou and Shuai Chen. Suppression of Tumorigenicity 5 Ameliorates Tumor Characteristics of Invasive Breast Cancer Cells via ERK/JNK Pathway. Frontiers in Oncology, 28 July 2021, https://doi.org/10.3389/fonc.2021.621500

7.        Zhao Y, Lu C, Wang H, Lin Q, Cai L, Meng F, Tesfaye EB, Lai HC, Tzeng CM. Identification of hsa-miR-1275 as a Novel Biomarker Targeting for Human Epilepsy of Unknown Etiology. Mol Ther Methods Clin Dev. 2020 Oct14;19:398-410. doi:10.1016/j.omtm.2020.10.005. PMID: 33251277; PMCID:PMC7677659.

8.        Lin TL, Lu CC, Lai WF, Wu TS, Lu JJ, Chen YM, Tzeng CM, Liu HT, Wei H, Lai HC. Role of gut microbiota in identification of novel TCM-derived active metabolites. Protein Cell. 2021 May;12(5):394-410. doi:10.1007/s13238-020-00784-w. Epub 2020 Sep 15. PMID: 32929698; PMCID: PMC8106560.

9.        Lin TL, Shu CC, Chen YM, Lu JJ, Wu TS, Lai WF, Tzeng CM, Lai HC, Lu CC. LikeCures Like: Pharmacological Activity of Anti-Inflammatory Lipopolysaccharides From Gut Microbiome. Front Pharmacol. 2020 Apr 30;11:554. doi:10.3389/fphar.2020.00554. PMID: 32425790; PMCID: PMC7212368.

10.     Zhao Y, Wang HL, Li TT, Yang F, Tzeng CM. Baicalin Ameliorates Dexamethasone-Induced Osteoporosis by Regulation of the RANK/RANKL/OPG Signaling Pathway. Drug Des Devel Ther. 2020 Jan 15;14:195-206. doi:10.2147/DDDT.S225516. PMID:32021104; PMCID: PMC6970258.

11.     Huang WQ, Ye HM, Cai LL, Ma QL, Lu CX, Tong SJ, Tzeng CM, Lin Q. The Associations of Variants With Leukoaraiosis in Chinese Population. Front Genet. 2019 Jul 23;10:615. doi:10.3389/fgene.2019.00615. PMID: 31396257; PMCID: PMC6664056.

12.     Zhu J, Deng L, Chen B, Huang W, Lin X, Chen G, Tzeng CM, Ying M, Lu Z. Magnesium-dependent Phosphatase (MDP) 1 is a Potential Suppressor of Gastric Cancer. Curr Cancer Drug Targets. 2019;19(10):817-827. doi:10.2174/1568009619666190620112546. PMID: 31218958.

13.     Huang J, Alexey S, Li J, Jones T, Grande G, Douthit L, Xie J, Chen D, Wu X, Michael M, Xiao C, Zhao J, Xie X, Xie J, Chen XL, Fu G, Alexander G, Tzeng CM. Correction: Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies. Leukemia. 2019 Sep;33(9):2341. doi:10.1038/s41375-019-0484-y. Erratum for: Leukemia. 2019 Sep;33(9):2315-2319.PMID: 31097784.

14.     Zhao Y, Cai LL, Wang HL, Shi XJ, Ye HM, Song P, Huang BQ, Tzeng CM. 1,25-Dihydroxyvitamin D3 affects gastric cancer progression by repressing BMP3 promoter methylation. Onco Targets Ther. 2019 Mar 28;12:2343-2353. doi:10.2147/OTT.S195642. PMID: 30992671; PMCID: PMC6445188.

15.     Huang WQ, Lin HN, Lin Q, Tzeng CM. Susceptibility Weighted Imaging (SWI) Recommended as a Regular Magnetic Resonance Diagnosis for Vascular Dementia to Identify Independent Idiopathic Normal Pressure Hydrocephalus Before Ventriculo-Peritoneal (V-P) Shunt Treatment: A Case Study. Front Neurol. 2019 Mar 29;10:262. doi:10.3389/fneur.2019.00262. PMID: 30984097; PMCID: PMC6449466.

16.     Huang J, Alexey S, Li J, Jones T, Grande G, Douthit L, Xie J, Chen D, Wu X,Michael M, Xiao C, Zhao J, Xie X, Xie J, Chen XL, Fu G, Alexander G, Tzeng CM. Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignancies. Leukemia. 2019 Sep;33(9):2315-2319. doi:10.1038/s41375-019-0455-3. Epub 2019 Apr 8. Erratum in: Leukemia. 2019 May 16; PMID: 30962578.

17.     Chen S, Wang H, Li Z, You J, Wu QW, Zhao C, Tzeng CM, Zhang ZM. Interaction of WBP2 with ERα increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. Br J Cancer. 2018 May 1;119(2):182-192. doi:10.1038/s41416-018-0119-5. PMID: 29937544; PMCID: PMC6048156.

18.     Huang WQ, Yi KH, Li Z, Wang H, Li ML, Cai LL, Lin HN, Lin Q, Tzeng CM. DNA Methylation Profiling Reveals the Change of Inflammation-Associated ZC3H12D in Leukoaraiosis. Front Aging Neurosci. 2018 May 23;10:143. doi:10.3389/fnagi.2018.00143. PMID: 29875652; PMCID: PMC5974056.

19.     Li Z, Chen S, Yang Y, Zhuang X, Tzeng CM. Novel biomarker ZCCHC13 revealed by integrating DNA methylation and mRNA expression data in non-obstructive azoospermia. Cell Death Discov. 2018 Feb 26;4:36. doi:10.1038/s41420-018-0033-x. PMID: 29531833; PMCID: PMC5841273.

20.     Chen S, Zhang Y, Wang H, Zeng YY, Li Z, Li ML, Li FF, You J, Zhang ZM, Tzeng CM. WW domain-binding protein 2 acts as an oncogene by modulating the activity of the glycolytic enzyme ENO1 in glioma. Cell Death Dis. 2018 Mar 1;9(3):347. doi:10.1038/s41419-018-0376-5. PMID: 29497031; PMCID: PMC5832848.

21.     Li Z, Tzeng CM. Integrated Analysis of miRNA and mRNA Expression Profiles to Identify miRNA Targets. Methods Mol Biol. 2018;1720:141-148. doi:10.1007/978-1-4939-7540-2_10. PMID: 29236256.

Tel: +86-13720890533

Email:  cmtzeng@xmu.edu.cn